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Paraoxonase polymorphisms are not associated with cardiovas- Cardiovascular disease (CVD) is the main cause of
cular risk in renal transplant recipients. morbidity and mortality in renal transplant recipients
Background. Paraoxonase (PON1) gene variants have been [1–3]. An increased prevalence of known risk factors for
identified as risk factors for cardiovascular disease (CVD).
CVD, such as diabetes, smoking, hypertension, and lipidThere are two common PON1 polymorphisms at position 55
abnormalities, may partly explain the accelerated devel-(Leu-Met change) and 192 (Gln-Arg change) of the amino
opment of atherosclerosis following renal transplanta-acid chain. Leucine at position 55 and arginine at position 192
have been associated with increased cardiovascular risk. The tion [1]. Furthermore, the number of acute graft rejection
increased prevalence of CVD in renal transplant recipients episodes [1] and hyperhomocysteinemia [4] also contrib-
can be only partly explained by the increased prevalence of ute to the higher cardiovascular risk in renal transplant
conventional risk factors.
recipients. Many of these factors may lead to increasedMethods. We therefore investigated PON1 polymorphisms
oxidative stress and consequently increased oxidation ofin renal transplant recipients (N 5 491) with (N 5 103) and
low-density lipoprotein (LDL), now recognized as a keywithout CVD (N 5 388) using polymerase chain reaction-
restriction fragment length analysis. PON1 polymorphisms and early event in the development of atherosclerosis [5].
their associated PON1/arylesterase activities were also assessed Epidemiological studies show a strong inverse correla-
in a subgroup of patients (N 5 165). tion between plasma levels of high-density lipoprotein
Results. The genotype distribution and allele frequencies for (HDL) and the development of atherosclerosis [6]. Tra-both polymorphisms were similar in both groups. The frequen-
ditionally, this has been attributed to the role of HDLcies for LL, LM, and MM genotypes for the 55 position in
in reverse cholesterol transport, but recent evidence indi-patients with CVD were 0.39, 0.51, and 0.10, respectively, com-
pared with 0.43, 0.43, and 0.14 in patients without CVD (P 5 cates that HDL can also protect LDL against oxidation
0.31). The distribution for the QQ, QR, and RR genotypes at [7–9]. The underlying mechanism by which HDL inhibits
the 192 position were 0.48, 0.43, and 0.09, respectively, in pa- LDL oxidation is not currently clear. However, there is
tients with CVD compared with 0.46, 0.46, and 0.08 in patients increasing evidence that paraoxonase (PON1), an en-without CVD (P 5 0.8). There were highly significant differ-
zyme closely associated with an apo A-I and clusterin-ences in serum activities of PON1/arylesterase between geno-
containing HDL subspecies, may be involved. This en-types defined by 55 and 192 polymorphisms. Leucine at position
55 and arginine at position 192 were associated with higher zyme has been shown to inhibit the oxidative modification
activities. of LDL during copper oxidation in vitro [10, 11], possibly
Conclusion. These data indicate that there is no association by destroying active phospholipids in minimally oxidized
between the PON1 gene variants, conferring higher enzyme LDL [12]. PON1 may therefore protect against the in-
activity, and the increased cardiovascular risk in renal trans-
duction of inflammatory responses in arterial wall cells.plant recipients.
There are two common DNA polymorphisms within
the PON1 gene. One is located at amino acid position
55 and is due to a leucine (L allele) and methionineKey words: transplantation, PON1 polymorphisms, genotypes, enzyme
activity, cardiovascular disease, diabetes. (M allele) interchange; the second one is at amino acid
position 192 and is caused by an interchange of glutamineReceived for publication June 16, 1998
(Q allele) and arginine (R allele) [13, 14]. Both polymor-and in revised form January 29, 1999
Accepted for publication February 15, 1999 phisms have been identified as genetic risk factors for
CVD in diabetes [15–17]. The 192R and 55L alleles have 1999 by the International Society of Nephrology
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been found to be independently associated with in- angiography or having no clinical history of heart disease
(CVD2, N 5 388). In the CVD1 group, CVD wascreased cardiovascular risk, and the association of the
192R allele and CVD has been confirmed in nondiabetic apparent in 28 subjects prior to transplantation, and ex-
cluding these subjects from the analysis did not changepatients [18]. Furthermore, a race-specific association
between the 192R allele and CVD has been reported in the results.
Venous blood samples were taken after an overnightan Asian Indian subpopulation of Singapore, whereas
there was no association between the 192 polymorphism fast. Serum was separated by centrifugation at 1200 g
within 45 minutes of venipuncture and was stored atand CVD in a Chinese subpopulation [19]. However,
several studies have reported no association between the 2208C until further analysis.
Serum was available from 165 renal transplant recipi-192 polymorphism and CVD [20–22]. This prompts the
question of whether the association of the 192R allele ents to investigate the association of PON1 polymor-
phisms and PON1/arylesterase activities. The genotypeand atherosclerosis is confined to only particular ethnic
populations or patient groups. distribution of the 55 and 192 polymorphism in this sub-
group of patients was not different from the distributionThe mechanism by which these PON1 polymorphisms
increase susceptibility to CVD is unknown. Both poly- in the total study population. For the 55 polymorphism,
the frequencies of the L and M alleles in the total popula-morphisms give rise to different enzyme activities toward
paraoxon, with the 192R and 55L alleles being associated tion were 0.65 and 0.35, respectively, compared with 0.62
and 0.38 in the subgroup. For the 192 polymorphism,with high PON1 activity [14, 16]. The effect of the 192
polymorphism, however, is reversed with other exoge- the frequencies of the Q and R alleles were identical in
the two groups: 0.69 and 0.31, respectively. Furthermore,nous substrates such as diazoxon, soman, and sarin,
whereas activity toward phenylacetate is not altered [23]. serum from 109 healthy control subjects was also studied
to compare PON1 activity between renal transplant pa-The use of phenylacetate as substrate is therefore an
tients and healthy control subjects. DNA was not avail-estimate for PON1 mass and is then referred to as aryles-
able from the healthy control subjects. Hence, the pheno-terase activity. The fact that PON1 activity is reduced
type for the 192 polymorphism in the controls wasin a number of pathological conditions, including post-
determined using the dual-substrate method describedmyocardial infarction [24], familial hypercholesterol-
by Eckerson et al [29]. The phenotype distribution foremia [25], diabetes [25, 26], and chronic renal failure [27,
the 192 polymorphism between patients and controls28], supports the hypothesis that altered enzyme activity
was similar. The frequencies of the QQ, QR, and RRmay provide a mechanism by which PON1 polymor-
phenotypes in the controls were 0.43, 0.47, and 0.10,phisms could influence cardiovascular risk.
respectively, compared with 0.47, 0.44, and 0.09 in theWe have therefore investigated whether PON1 55 and
patients. The allele frequencies for the Q and R were192 DNA polymorphisms are associated with increased
also similar: 0.67 and 0.33 in the controls, respectively,cardiovascular risk in patients following renal trans-
compared with 0.69 and 0.33 in the renal transplant recip-plantation. We have also assessed whether PON1 en-
ients.zyme activity is associated with these PON1 DNA poly-
morphisms in renal transplant recipients and whether
DNA extraction and genotypingPON1/arylesterase activities are altered in renal trans-
Genomic DNA was obtained from peripheral bloodplant recipients compared with healthy control subjects.
leukocytes as described by Miller, Dykes, and PoleskyFurthermore, we have assessed the role of the apoJ/
[30]. PON1 55 and 192 genotyping was performed usingPON1 ratio as a marker for atherosclerosis in this patient
polymerase chain reaction (PCR)-restriction fragmentgroup.
length analysis, essentially as described by Humbert et
al [14]. Twenty-five microliter PCR mixes were set up,
METHODS containing 10 mm Tris-HCl, pH 8.3, 50 mm KCl, 1.5 mm
All chemicals were purchased from Sigma Chemical MgCl2, 0.001% gelatine, 0.2 mm dNTPs, 0.25 mm of each
Company (Poole, Dorset, UK) unless otherwise stated. PON1 55 oligonucleotide primers (forward 59GAAG
AGTGATGTATAGCCCCAG39, reverse 59TTTAAT
Subjects and blood sampling CCAGAGCTAATGAAAGCC39) or PON1192 oligo-
This study was performed in accordance with the nucleotide primers (forward 59TATTGTTGCTGTGG
guidelines of the ethics committee of the Queen’s Uni- GACCTGAG39, reverse 59CACGCTAAACCCAAA
versity of Belfast. Genomic DNA was available from TACATCTC39), 0.5 U of Amplitaq Gold DNA polymer-
491 renal transplant recipients. All subjects were Cauca- ase (Perkin-Elmer, Warrington, UK), and 0.1 mg DNA.
sian and were classified as having coronary heart disease A Techne Cyclogene DNA thermocycler was em-
(CVD1, N 5 103) if they had a history of myocardial ployed with PCR conditions as follows: 958C for nine
minutes (enzyme-activation step), then 35 cycles con-infarction or ischemic heart disease proven by coronary
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sisting of 958C for one minute, either 608C (55 polymor- an intra-assay coefficient of variation (CV) of 2.9% and
an interassay CV of 3.0% (N 5 10).phism) or 588C (192 polymorphism) for one minute and
728C for one minute, followed by a final extension step Second, the PON1 activity was measured in an aryles-
terase assay using phenylacetate as substrate. The initialof 728C for 10 minutes. The PON1 55 (170 bp) and 192
(99 bp) PCR products were subsequently digested with rate of hydrolysis (first 90 seconds) was recorded at 270
nm on a Hitachi U-2000 spectrophotometer [32]. Briefly,10U Hsp92II (Promega, Southampton, UK) and 8U
AlwI (New England Biolabs, Hitchin, UK), respectively, 5 ml of serum samples were added to 3 ml of the reaction
mixture containing 1 mm phenylacetate, 20 mm Tris-HClat 378C for 16 hours and were then resolved on a 3%
agarose gel. Alleles L and M for the PON1 55 position buffer, and 1 mm CaCl2 at pH 8.0 and 258C. Blanks
without enzyme were used to correct for spontaneouswere assigned based on the presence of a 170 bp (undi-
gested) fragment and 126 and 44 bp (digested) fragments, hydrolysis of phenylacetate. Enzymatic activity was cal-
culated from the molar extinction coefficient 1310respectively. For the 192 polymorphism, alleles 192 Q
and 192 R were assigned based on the presence of a 99 m21cm21. Arylesterase activity is expressed as U/ml se-
rum under the assay conditions mentioned earlier here.bp (undigested) fragment and 69 and 30 bp (digested)
fragments, respectively. One unit of arylesterase activity is defined as 1 mmol
phenol generated per minute under the previously men-
Lipid and apoprotein determination tioned conditions. The intra-assay CV was 2.9%; the
interassay CV was 6.5% (N 5 10).Total cholesterol, HDL cholesterol, and triglycerides
were determined using enzymatic assays (Boehringer,
ApoJ concentrationsMannheim, Germany) on a Cobas Fara analyzer. LDL
cholesterol concentrations were calculated by the for- A single antibody enzyme-linked immunosorbent
assay, similar to the one described by Høga˚sen et al [33],mula of Friedewald, Levy and Fredrickson [31]. If triglyc-
erides were greater than 4.0 mmol/liter, low density lipo- was used to determine apoJ concentrations in human
plasma. Briefly, microtiter plates (Nunc Maxisorp,protein (LDL) cholesterol and high density lipoprotein
(HDL) cholesterol were measured using an ultracentrif- Roskilde, Denmark) were coated with 50 ml of human
plasma or serum [diluted 1:8000 in phosphate-bufferedugation procedure to separate very low density lipopro-
tein (VLDL) coupled with magnesium/phosphotung- saline (PBS) containing 0.2% Tween] and incubated for
20 hours at 48C. The plates were then aspirated andstate precipitation. Apolipoprotein (apo) A-I, apo A-II,
and apo B were measured by rate immunonephelometric washed four times with PBS containing 0.2% Tween.
Monoclonal antibody to purified apoJ (Quidel, Santechniques using commercially available kits with anti-
sera and standards supplied by the manufacturer (Ran- Diego, CA, USA) was diluted 1:8000 in PBS and 100 ml
of diluted antibody were then added to each well. Platesdox, Crumlin, UK, for apo A-I and apo B; Immuno,
Kent, UK, for apo A-II). were incubated for 60 minutes at room temperature. The
plates were aspirated and again washed four times with
PON1/arylesterase activities PBS containing 0.2% Tween. The secondary antibody,
a goat antimouse HRP-conjugated antibody (Dako,Paraoxonase (PON1) activity was determined using
two different substrates. First, the rate of hydrolysis of Glostrup, Denmark), was diluted 1:2000 in PBS, and 100
ml of this dilution were added to each well. Plates wereparaoxon was measured by monitoring the increase in
absorbance at 412 nm and 258C due to the formation of incubated for 60 minutes at room temperature. After
incubation, plates were aspirated and washed four timesp-nitrophenol. The serum sample to be tested was added
to a cuvette containing 1 mm paraoxon, 1 mm CaCl2 and with PBS containing 0.2% Tween. Finally, 100 ml of the
chromogenic enzyme substrate OPD [2.5 mg OPD in 1050 mm Tris-HCl buffer at pH 8.0 or 50 mm glycine/NaOH
buffer at pH 10.5. Blanks contained substrate without ml citrate buffer 1 4.7 ml H2O2 (30%); citrate buffer: 58
mm Na2HPO4, 13.7 mm citric acid, pH 5.6] were addedenzyme. The amount of p-nitrophenol generated was
calculated from the molar extinction coefficients at pH to each well and incubated in the dark for 30 minutes
at room temperature. The reaction was stopped with 508.0 and pH 10.5, which were 17,000 and 18,290 m21cm21,
respectively [32]. PON1 activity is expressed as U/ml ml of 2.5 m H2SO4, and plates were read in a plate reader
at 490 nm. In order to calculate apoJ concentrations, aserum, with one unit of PON1 activity being defined as
1 nmol p-nitrophenol generated per minute under the standard curve using purified apoJ diluted in PBS (Qui-
del) was included within each plate with apoJ concentra-previously mentioned conditions. In preliminary experi-
ments, prior incubation of serum with eserine was carried tions of 0, 62.5, 125, 250, 500, and 1000 mg/ml. The stan-
dard curve was linear over this range of concentrationsout, and this resulted in no diminution of PON1 activity,
indicating that there was no significant contribution from (r 2 . 0.95). Blanks (PBS only) were also included to
ensure that there was no nonspecific binding of the anti-nonspecific hydrolysis of paraoxon. The assay was auto-
mated and performed on a Cobas Fara analyzer, with apoJ antibody or the secondary antibody to the plates.
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Table 2. Genotype distribution of the PON1 polymorphisms atTable 1. Characteristics of renal transplant recipients
with and without CVD positions 55 and 192 in the total study population (N 5 491) and
genotype distribution and allele frequency for the PON1
CVD1 CVD2 polymorphisms at positions 55 and 192 in CVD2
Parameter (N 5 103) (N 5 388) P value and CVD1 patients
Age years 55.8610.3 43.1616.0 ,0.001 QQ QR RR Total
Sex M/F 70/33 234/154 0.191
Smoking yes/no 42/31 115/175 ,0.01 LL 54 117 39 210
LM 114 103 1 218Diabetes yes/no 22/81 27/361 ,0.001
BMI kg/m2 27.665.2 26.365.4 0.053 MM 59 4 0 63
Total 227 224 40 491Systolic blood pressure mm Hg 136.8617.0 131.0617.4 ,0.01
Diastolic blood pressure mm Hg 78.3610.9 78.8610.4 0.743
CVD1 CVD2
Abbreviations are: CVD, cardiovascular disease; BMI, body mass index. Frequencies (N 5 103) (N 5 388) P value
55 Polymorphism
Genotype
LL 0.39 0.43
LM 0.51 0.43Each sample or standard was assayed in triplicate. The
MM 0.10 0.14 0.31
intra-assay CV was 7.9%; the interassay CV was 8.4%. Allele
L allele 0.65 0.65To minimize interassay variations, a quality control se-
M allele 0.35 0.35 1.00rum was included within each plate.
192 Polymorphism
Genotype
Statistical analysis QQ 0.48 0.46
QR 0.43 0.46The Kolmogorov–Smirnov goodness of fit test was
RR 0.09 0.08 0.80
used to test data for normality. Comparisons between Allele
Q allele 0.70 0.69 0.85groups were made by Student’s unpaired t-test or Mann–
R allele 0.30 0.31Whitney U-test depending on data distribution. Cat-
egorical variables were compared by a chi-square test.
Genotype distribution, allele frequencies, and Hardy–
Weinberg equilibrium were also tested by a chi-square
also no associations between PON1 polymorphisms andtest. Multivariate analysis was performed using a logistic
CVD in diabetic and nondiabetic subjects consideredregression model. The association between PON1 poly-
separately.morphisms, PON1/arylesterase activities, and lipid pa-
Associations of the 55 and 192 polymorphisms andrameters were tested by one-way analysis of variance or
age, sex, PON1/arylesterase activities, serum lipids, andKruskal–Wallis test.
apoproteins are shown in Tables 3 and 4, respectively.
The mean 6 sd age of the subgroup of 165 patients was
RESULTS 43 6 15 years. There were 99 male and 66 female sub-
The characteristics of renal transplant recipients with jects. There were no significant differences in age, sex
and without CVD are shown in Table 1. Conventional distribution, and lipid and apoprotein concentrations be-
risk factors, including age, smoking status, prevalence of tween the different genotypes of each polymorphism.
diabetes, and systolic blood pressure were higher in the There were, however, marked differences in PON1 and
CVD1 group. Logistic regression analysis showed that arylesterase activities between genotypes for each poly-
age (P , 0.001), diabetes (P , 0.001), sex (P 5 0.026), morphism. MM homozygotes for the 55 polymorphism
and smoking (P 5 0.036), were significantly associated have significantly decreased PON1 and arylesterase ac-
with the presence of CVD. tivities compared with LL homozygotes (Table 3). Me-
The distribution of both PON1 55 and PON1192 geno- dian (interquartile range) PON1 activities in MM sub-
types were in Hardy–Weinberg equilibrium. The distri- jects were 26.1 (22.3 to 29.7) U/ml serum at pH 8.0 and
66.6 (58.5 to 80.1) U/ml serum at pH 10.5 compared withbution of the two polymorphisms in the total 491 patients
is shown in Table 2. Both distributions corresponded to 103.1 (67.3 to 148.0) U/ml serum at pH 8.0 and 187.8
(132.0 to 256.2) U/ml serum at pH 10.5 in LL subjectsthose observed in other Caucasian populations [15, 16].
A linkage disequilibrium leading to a rare association of (P , 0.001). Arylesterase activity was also significantly
reduced in MM subjects with a mean 6 sd of 71.7 6methionine at position 55 and arginine at position 192
was also observed in our study [16]. 16.8 versus 95.3 6 16.2 U/ml serum in LL subjects (P ,
0.001).No association between the 55 and 192 PON1 poly-
morphisms and CVD was found in this study (Table 2). Similar differences were found for the 192 polymor-
phism. Both PON1 and arylesterase activities were sig-The genotype distributions and the allele frequencies
of the 55 and 192 polymorphisms were similar in renal nificantly reduced in QQ subjects (Table 4). The median
(interquartile range) PON1 activities in QQ subjectstransplant recipients with and without CVD. There were
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Table 3. PON1/arylesterase activities, lipid and apoprotein concentrations as a function of the 55 polymorphism
in a subgroup of patients (N 5 165)
LL LM MM
Parameter (N 5 65) (N 5 76) (N 5 24)
Age years 41615 45 615 44 616
Sex M/F 48/17 40/36 11/13
Paraoxonase, pH 8.0 U/ml serum 103.1 53.7 26.1a
range (67.3–148.0) (35.9–101.9) 22.3–29.7)
PON1, pH 10.5 U/ml serum 187.8 117.0 66.6a
range (132.0–256.2) (89.7–176.0) (58.5–80.1)
Arylesterase, pH 8.0 U/ml serum 95.3616.2 86.2 617.1 71.7616.8a
Total cholesterol mmol/liter 6.0261.53 6.10 61.31 6.41 61.09
LDL cholesterol mmol/liter 3.7261.36 3.75 61.12 4.01 61.09
HDL cholesterol mmol/liter 1.1360.47 1.11 60.40 1.22 60.41
Triglycerides mmol/liter 2.25 2.48 2.12
(1.68–3.00) (1.77–3.62) (1.67–3.53)
Apo A-I mg/dl 180.32633.29 182.71 634.15 188.52 633.60
Apo A-II mg/dl 36.6368.85 36.28 67.52 37.91 69.32
Apo B mg/dl 108.06625.46 110.35 623.73 113.31 621.80
Data are means 6 sd, PON1 activities and triglycerides are median (interquartile range).
a P , 0.001
Table 4. PON1/arylesterase activities, lipid and apoprotein concentrations as a function of the 192 polymorphism
in a subgroup of patients (N 5 165)
QQ QR RR
Parameter (N 5 77) (N 5 73) (N 5 15)
Age years 45615 42 615 40 615
Sex M/F 43/34 44/29 12/3
PON1, pH 8.0 U/ml serum 34.8 102.5 199.4b
(28.1–42.3) (85.5–128.5) 171.8–223.4)
PON1, pH 10.5 U/ml serum 86.1 178.0 307.2b
(71.5–103.3) (145.2–221.9) (261.7–344.5)
Arylesterase, pH 8.0 U/ml serum 85.0618.5 87.9 615.6 100.1617.1a
Total cholesterol mmol/liter 6.1161.17 6.18 61.59 5.74 61.19
LDL cholesterol mmol/liter 3.7761.03 3.88 61.43 3.38 60.96
HDL cholesterol mmol/liter 1.1060.35 1.13 60.43 1.33 60.70
Triglycerides mmol/liter 2.43 2.31 2.02
(1.76–3.25) (1.68–3.39) (1.63–2.81)
Apo A-I mg/dl 181.34630.89 182.38 633.87 190.28 645.79
Apo A-II mg/dl 36.5767.51 35.88 67.95 40.81 612.43
Apo B mg/dl 112.20620.98 109.50 627.69 99.77 618.41
Data are means 6 sd, PON1 activities and triglycerides are median (interquartile range).
a P , 0.05
b P , 0.001
were 34.8 (28.1 to 42.3) U/ml serum at pH 8.0 and 86.1 PON1 activity (P , 0.001; Fig. 1) when passing from the
Q allele to the R allele, irrespective of the genotype(71.5 to 103.3) U/ml serum at pH 10.5 compared with
199.4 (171.8 to 223.4) U/ml serum at pH 8.0 and 307.2 defined by the 55 polymorphism. Arylesterase activity,
however, was similar in 192QQ and 192RR subjects(261.7 to 344.5) U/ml serum at pH 10.5 in RR subjects
(P , 0.001). Arylesterase activity was also significantly for a given genotype defined by the 55 polymorphism
(P 5 NS).reduced in QQ subjects with a mean 6 sd of 85.0 6 18.5
vs. 100.1 6 17.1 U/ml serum in RR subjects (P , 0.05). Table 5 shows the characteristics of renal transplant
recipients with (N 5 18) and without CVD (N 5 36)Enzyme activities as a function of 55 and 192 polymor-
phisms are shown in Figures 1 and 2. With paraoxon matched for age and sex. There were no differences
in total cholesterol, LDL cholesterol, HDL cholesterol,(P , 0.01; Fig. 1) and phenylacetate (P , 0.001; Fig. 2)
as substrates, there were significant decreases in activity triglycerides, and the total cholesterol/HDL cholesterol
ratio between renal transplant recipients with and with-when passing from the L allele to the M allele for a
given QQ genotype at the position 192. For a given QR out CVD. The genotype distribution for the 55 and 192
PON1 polymorphisms was also not different betweengenotype at the position 192, these decreases were less
evident. There were also highly significant increases in the two groups. Table 5 also demonstrates that PON1/
Hasselwander et al: Paraoxonase polymorphisms and CVD294
Table 5. Characteristics, PON1/arylesterase activities, apoJ
concentrations, apoJ/PON1 and apoJ/arylesterase ratios of renal
transplant recipients with and without CVD
CVD1 CVD2
Parameter (N 5 18) (N 5 36)
Age years 51.569.2 51.8611.1
Sex M/F 11/7 22/14
Total cholesterol mmol/liter 5.9961.14 6.1261.41
LDL cholesterol mmol/liter 3.8661.06 3.7561.20
HDL cholesterol mmol/liter 1.0660.31 1.0360.38
Triglycerides mmol/liter 2.27 (1.61–2.76) 2.73 (1.87–3.68)
Total cholesterol/HDL ratio 6.0461.86 6.4164.26
Arylesterase U/ml serum 88.3619.4 85.5617.4
PON1, pH 8.0 U/ml serum 57.6 (36.0–109.1) 55.4 (33.8–111.1)
PON1 pH 10.5 U/ml serum 111.3 (86.8–194.3) 116.7 (82.4–177.5)
AplJ lg/ml serum 286.56130.9 335.26113.1
ApoJ/PON1 ratio, pH 8.0 3.08 (1.78–9.74) 4.16 (2.71–11.30)
ApoJ/PON1 ratio pH 10.5 1.66 (1.06–4.04) 2.26 (1.46–4.43)
ApoJ/arylesterase ratio 3.3861.66 4.0161.62
Data are mean 6 sd. Triglycerides, PON1 activities and apoJ/PON1 ratios
are median (interquartile range).
Fig. 1. Paraoxonase (PON1) activity as a function of the 55 and 192
polymorphisms in the subgroup of patients (N 5 165).
in the renal transplant recipients with 79.6 6 16.7 U/ml
serum versus 69.6 6 16.7 U/ml serum in healthy control
subjects (P , 0.001). PON1 activity, however, was com-
parable between patients and controls: 66.5 (36.0 to
117.5) U/ml serum at pH 8.0 and 126.9 (88.4 to 195.0)
U/ml serum at pH 10.5 in patients versus 71.9 (37.8 to
110.4) U/ml serum at pH 8.0 and 145.7 (99.9 to 200.1)
U/ml serum at pH 10.5 in healthy control subjects. Eigh-
teen of the 165 renal transplant recipients had CVD;
however, the exclusion of these 18 patients did not alter
the results.
DISCUSSION
This is the first study investigating the association of
the 55 and 192 PON1 DNA polymorphisms and CVD
in renal transplant recipients, a group of patients with
markedly increased cardiovascular risk [1–3]. We have
demonstrated that neither the 55 nor the 192 PON1
DNA polymorphisms are associated with increased risk
Fig. 2. Arylesterase activity as a function of the 55 and 192 polymor- of CVD.
phisms in the subgroup of patients (N 5 165). The PON1 gene has been identified as a susceptibility
gene for CVD. The LL genotype defined by the 55 poly-
morphism and the RR genotype defined by the 192 poly-
morphism have been shown to be associated with in-arylesterase activities, apoJ concentrations, and apoJ/
creased cardiovascular risk in diabetic patients [15–17].PON1 and apoJ/arylesterase ratios were similar in renal
The association between the 192 polymorphism andtransplant recipients with and without CVD.
CVD may partly be attributable to the association ofTable 6 shows PON1 activity and lipid and apoprotein
the 55 polymorphism and CVD, due to linkage disequi-concentrations in patients following renal transplanta-
librium between the 55L and 192R alleles [16]. The asso-tion (N 5 165) compared with healthy control subjects
ciation of the 192R allele and cardiovascular risk has(N 5 109). The total cholesterol, LDL cholesterol, tri-
been confirmed in nondiabetic populations [18] and inglycerides, apo A-I, and apo B were all significantly in-
an Asian Indian subpopulation of Singapore [19], whichcreased in renal transplant recipients (P , 0.001),
is at an increased cardiovascular risk compared with thewhereas Apo A-II was decreased in the patient group
(P , 0.001). Arylesterase activity was significantly higher Chinese subpopulation of Singapore. The frequency of
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Table 6. Serum lipids, apoproteins and PON1 activities in renal transplant recipients compared to healthy control subjects
Patients Controls
Parameter (N 5 165) (N5 109) P value
Age years 43.6615.1 45.1617.0 NS
Sex M/F 100/65 51/58 ,0.05
Arylesterase, pH 8.0 U/ml serum 79.6616.7 69.6616.7 ,0.001
PON1, pH 8.0 U/ml serum 66.5 71.9
(36.0–117.5) (37.8–110.4) NS
PON1 pH 10.5 U/ml serum 126.9 145.7
(88.4–194.9) (99.9–200.1) NS
Total cholesterol mmol/liter 6.1161.37 5.3361.03 ,0.001
LDL cholesterol mmol/liter 3.7761.18 3.2960.98 ,0.001
HDL cholesterol mmol/liter 1.1360.43 1.2160.38 NS
Triglycerides mmol/liter 2.35 1.63
(1.73–3.26) (1.12–2.46) ,0.001
Apo AI mg/dl 182.34633.65 165.10635.35 ,0.001
Apo A-II mg/dl 36.5768.25 42.4667.85 ,0.001
Apo B mg/dl 109.78624.15 98.51624.81 ,0.001
Data are means 6 sd. PON1 activities and triglycerides are median (interquartile range).
the 192R allele in the Indian subpopulation was lower cific patient groups and ethnic populations with an asso-
ciation of the PON1 gene and CVD.compared with the Chinese subpopulation [19]. As in
these positive studies, the diagnosis of CVD in our pa- The mechanism by which the PON1 enzyme may in-
fluence susceptibility to CVD is still unclear. Severaltients was based on clinical grounds or coronary angiog-
raphy. It remains likely that asymptomatic disease was studies have shown associations between PON1 and
plasma lipids or apoproteins [37, 38], suggesting that thepresent in some subjects, but this is also the case for
previous studies in other groups. In addition, there have 192Q allele is associated with a less atherogenic lipid
profile [38]. We, however, did not find any differencesbeen three other negative studies looking at the 192
polymorphism and CVD [20–22] in patients with CVD in plasma lipids or apoproteins between the different
genotypes defined by the 55 and 192 polymorphisms,compared with healthy control subjects. This suggests
that the PON1 gene may only be a susceptibility gene which is in accordance with the findings of Blatter-Garin
et al in a diabetic population [16]. There is increasingfor CVD in certain patient or ethnic subgroups. The
PON1 gene is a member of a multigene family, including evidence that PON1 can inhibit the oxidation of LDL
[10, 11] and destroy biologically active lipid peroxidesPON2 and PON3 [34]. Sanghera et al have recently
shown that a common Cys-Ser polymorphism at codon in vitro [12]. This would suggest that high PON1 activity
is beneficial. High PON1 activity, however, is associated311 in the PON2 gene is associated with increased cardio-
vascular risk [35]. The frequency of the PON2311S allele with the 192R allele and 55L allele, both of which are
associated with increased susceptibility to CVD in diabe-was significantly higher in cases than in controls. This
association between the PON2311S and CVD was con- tes and specific ethnic populations [15–17, 19]. One possi-
ble explanation for this paradox is that the hydrolysis offined to PON1192R allele carriers. Likewise, the in-
creased cardiovascular risk of PON1192R allele carriers lipid peroxides by PON1 results in the formation of even
more harmful lysolipids [39]. It has therefore been pro-was present in only PON2311S allele carriers. As no
PON2 gene product has yet been found, it remains possi- posed that the balance between PON1 activity and other
HDL associated enzymes, such as platelet-activating fac-ble that the association between the PON2 gene and
CVD is due to linkage disequilibrium with the PON1 tor acetylhydrolase and lecithin cholesterol acyltransfer-
ase, is critical [39]. Alternatively, it has been shown thatpolymorphisms. Furthermore, it is also conceivable that
the so far observed associations between the PON1 and HDL isolated from subjects with 192RR or 55LL geno-
types was less efficient in hydrolyzing lipid peroxidesPON2 genes and CVD are due to linkage disequilibrium
with a functional mutation of the PON3 or another and hence less efficient in protecting LDL during copper-
induced oxidation, although the 192R and 55L allelesnearby gene. Although the physiological roles of PON2
and PON3 gene products are unknown, the PON2 gene exhibit high serum PON1 activity [40]. It is also conceiv-
able that the 192R and the 55L alleles are, in fact, associ-has recently been associated with elevated fasting plasma
glucose in type II diabetes mellitus [36]. Possible interac- ated with low PON1 activity toward its physiological
substrate. Both polymorphisms give rise to different en-tions at the gene level between PON1 and PON2 may
therefore affect the risk of CVD, especially in diabetic zyme activities toward paraoxon, with the 192R and 55L
alleles being associated with high PON1 activity [23].populations. Further studies are needed to identify spe-
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The effect of the 192 polymorphism, however, is reversed subfraction of HDL, which also contains PON1 [45]. In
atherosclerotic lesions, it can be found colocalized withwith other exogenous substrates such as diazoxon, so-
man, and sarin, whereas activity toward phenylacetate PON1 [46]. ApoJ has been suggested to transport lipids
[47] and may hence be involved in reverse cholesterolis not altered [23]. It is therefore possible that 192R and
55L alleles exhibit low PON1 activity toward oxidized transport [47]. Furthermore, preincubation of LDL or
artery wall cells in coculture with purified apoJ led to aphospholipids, its hypothesized natural substrate, and
are hence associated with increased cardiovascular risk. dose-dependent inhibition of LDL-induced lipid hydro-
peroxide formation, monocyte chemoattractant pro-Recent experiments in PON1 knockout mice demon-
strated that HDL isolated from these mice did not inhibit tein-1 production, and monocyte transmigration in vitro
[48]. These properties of apoJ imply that apoJ may beoxidized LDL-induced monocyte transmigration [41].
Furthermore, PON1 knockout mice showed increased implicated in atherogenesis. Thus, Navab et al reported
that serum apoJ levels of patients with CVD, who hadatherosclerotic lesion formation. These findings suggest
that PON1 may protect against the induction of inflam- normal lipid profiles, were markedly increased, whereas
PON1 activity was decreased [48]. This resulted in amatory responses in arterial wall cells, and low PON1
activity may be a risk factor for CVD regardless of the significant rise in the apoJ/PON1 ratio in patients with
CVD compared with healthy control subjects. It wasPON1 genotype.
Both PON1 55 and 192 DNA polymorphisms are asso- therefore proposed that the apoJ/PON1 ratio is a better
marker for atherosclerosis than the total cholesterol/ciated with differences in PON1/arylesterase activities in
renal transplant recipients. Subjects with genotypes HDL cholesterol ratio [48]. Our results, however, suggest
that neither the total cholesterol/HDL cholesterol nor55LL or 192RR exhibit increased PON1 and arylesterase
activities (Tables 3 and 4). For a given 55 genotype, the apoJ/PON1 and apoJ/arylesterase ratios are good
predictors for the presence of atherosclerosis in renalhowever, there were no differences in arylesterase activ-
ity between 192QQ and 192RR genotypes. For a given transplant recipients. All ratios were similar in patients
with and without CVD. Navab et al also suggested that192 genotype, the 55 polymorphism remains associated
with differences in PON1 and arylesterase activities. Be- there was a nonsignificant trend toward lower PON1
activity in patients with CVD [48]. PON1 activity wascause arylesterase is an estimate for PON1 mass, it seems
that the 55 polymorphism is associated with differences also reported to be lower in patients after myocardial
infarction [24]. Changes in PON1 activity after infarction,in PON1 mass and, as a consequence, also with differ-
ences in PON1 activity. This is in agreement with Blatter- however, may be a consequence of CVD rather than a
predisposing factor. We did not find any differences inGarin et al, who looked at PON1 activity and mass in a
diabetic population [16], but differs from the findings of PON1/arylesterase activities in patients with and without
CVD, which is in keeping with the findings of SecchieroMackness et al, who found that neither polymorphism
influenced PON1 mass in a healthy Caucasian population et al [49]. In contrast to the findings of Navab et al, who
found markedly increased levels of apoJ and therefore[42]. However, it is also possible that the differences in
arylesterase activity do not reflect PON1 mass differ- higher apoJ/PON1 ratios in patients with CVD [48], our
study showed no differences in apoJ concentrations andences. This would be the case if renal transplantation
were to alter the affinity of arylesterase for its substrate apoJ/PON1 ratios between patients with CVD and con-
trols. The study of Navab et al, however, only comparedphenylacetate. In regard to PON1 activity, the associa-
tion between the 192 polymorphism and PON1 activity PON1 activity, which varies substantially between geno-
types defined by the PON1 55 and 192 polymorphisms.in our study is stronger compared with the one between
the 55 polymorphism and PON1 activity, suggesting that It is therefore possible that the trend toward decreased
PON1 activity in patients with CVD was caused by aboth polymorphisms modulate PON1 activity indepen-
dently. greater proportion of QQ subjects in this group. Because
of the genotype-dependent variations in PON1 activity,The reason for these polymorphism-associated differ-
ences in PON1 activity and mass is still unclear. The apoJ/PON1 ratios also vary between genotypes defined
by the PON1 polymorphism at the position 55 and 192.active site of the enzyme and the catalytic mechanisms
remain to be elucidated [43], but it has been suggested It is therefore essential to also compare apoJ/arylesterase
ratios between patients with CVD and controls, as ar-that the lipid environment of the enzyme may influence
its activity. If HDL composition is altered in renal trans- ylesterase activity and consequently the apoJ/arylester-
ase ratio are not genotype-specific.plant recipients, this may therefore contribute to altered
PON1 activity. The polymorphism at position 55 occurs In a previous study, we have shown that PON1 activity
is reduced in patients with chronic renal failure com-in the NH2-terminal hydrophobic region of the enzyme
[44] and may therefore facilitate binding of PON1 to pared with healthy control subjects [28]. This was due
to a decrease in PON1 specific activity (abstract; Hassel-HDL.
ApoJ is an apoprotein bound to an apoA-I–containing wander et al, J Am Soc Nephrol 8:A2880, 1997), possibly
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